University of Colorado
Anschutz Medical Campus

Institutional Biosafety Committee (IBC)
Zoom Meeting Minutes
26 October 2026
9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:

[redacted] (JA)
Dr. [redacted] (EC)
Dr. [redacted] (HD)
Dr. [redacted] (PD)
Dr. [redacted] (MF)
Dr. [redacted] (BH)
[redacted] (EK)
Dr. [redacted] (AL)***
Dr. [redacted] (CM)
[redacted] (SM)*
Dr. [redacted] (Co-chair) (BM)
Dr. [redacted] (Co-chair) (TM)
[redacted] (ZJW)
[redacted] (ZW)

Non-voting IBC Members/Guests:

[redacted] (AA)
[redacted] (JAA)
[redacted] (QB)
[redacted] (JW)
[redacted] (CW)**

I. **Call to Order:** 9:00am (Mountain Time)

II. **Conflict of Interest:**
- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

III. **Review and Approval of Previous Minutes:** 28 September 2026
The minutes were reviewed and approved by the IBC.
Approved = 9
Opposed = 0
Abstained = 4 (EC, ZJW, HD, and AL)

IV. **IBC Administrative Business:**
1. **IBC Administrative Changes:**
   i. JW announced potential new IBC member observing meeting: JAA
2. **Protocol Closures:**
   i. [redacted] - # 1291
   ii. [redacted] - # 1761
3. **Protocol Transfers:** None

Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:
During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences,

the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

*SM joined the meeting at 9:05am.

V. New Business:

1. **Environmental Health and Safety Office Updates:** None
2. **Biosafety Office Updates:**
    a. BH updated the IBC on the final assessment findings regarding the recent CDC-NAC visit for PV containment facility readiness and upcoming response deadline.
    b. TM briefly detailed the *United States Government Policy for Stopping High-Risk Life Sciences Research* and the institution's working group (IRE) in charge of implementing policy changes. IBC to be updated of potential implications for committee as policy announcements become available.

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Monge Urrea, Jorge - # 24-2523: *A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects With Relapsed/Refractory Multiple Myeloma*
2. Piquet, Amanda - # 24-0669: *A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Participants with Generalized Myasthenia Gravis*
3. Walleigh, Diana - # 25-2216: *Phase 1/2 First-in-Human Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants with Pitt Hopkins Syndrome*
4. Patel, Sapna - # 25-0004: *A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma*
5. GBF (26-270A_BC2_Ped) - # 26-0270 – Risk assessment
6. GBF (26-021A_BC2_Adult) - # 26-0021 – Risk assessment
7. Knupp, Kelly - # 25-2098: *ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children with SCN1A-positive Dravet Syndrome*
8. Angelos, Mathew - # 25-0718: *Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T Cells in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (HR-MDS)*
9. Pinto, Navin - # 25-2172: *An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects with Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)*

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

1. **Lieu, Christopher- # 26-0021: A Phase 1, Open Label, Dose-Escalation Trial of B7H3-targeting, CXCR2-enhanced (BC2) Chimeric Antigen Receptor T-cell (CAR-T) Therapy for Adult Advanced Colorectal Cancer**
   Biosafety level: BSL-2
   NIH Section(s): III-C
   Approved = 14

Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including resolving conflicting SOP details and providing additional details regarding the in vivo biodistribution data.

2. **Jimeno, Antonio - # 26-1823: Primary: A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors/ Substudy 2: A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced**
Biosafety level: BSL-2
NIH Section(s): III-C
Approved = 14
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with no further committee concerns.

**CW left the meeting at 9:26am.

VIII. New Laboratory Protocol Reviews:

1. [redacted] **- # 1783: Studying the immune system in solid tumors**
Biosafety level: BSL-2, ABSL-1
NIH Section(s): III-F
Approved = 14
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address selecting appropriate IBC protocol checkboxes and clarifying details in the IBC protocol form.

***AL left the meeting at 9:34am.

2. [redacted] **- # 1784: Mechanistic Studies of Cancer Immunoediting in Skin Disease**
Biosafety level: BSL-2, ABSL-1
NIH Section(s): III-D-4, III-D-2, III-D-1, III-E-1, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including selecting appropriate IBC protocol checkboxes, updating BSL checkboxes and procedure details, providing transportation/shipping documents as needed, and updating research narrative details for clarity.

IX. De Novo Laboratory Protocol Reviews:

1. [redacted] **- # 1129: Neural substrates of normal and dysfunctional motor control**
Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
NIH Section(s): II-D-1, III-D-4-a, III-F
Approved = 13
Opposed = 0

Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address IBC protocol checkboxes, update engineering control and procedure details, and select appropriate PPE checkboxes.

2. [redacted] **- # 1139: Mechanisms of albumin and immune complex handling in the glomerulus**
Biosafety level: BSL-1, BSL-2, ABSL-1
NIH Section(s): III-D-1, III-D-2, III-E-1, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address adding additional IBC protocol sections and procedures, updating associated protocol expiration dates, procedures, and research narrative details for clarity, and selecting appropriate IBC protocol checkboxes.

3. [redacted] **- # 1484: Biochemical, biophysical and biological characterization of families of proteins**
Biosafety level: BSL-2
NIH Section(s): III-D-2, III-E-1, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating research narrative for clarity and selecting appropriate PPE checkboxes.

4. [redacted] **- # 1495: Fetal and neonatal growth and metabolism**
Biosafety level: BSL-2, ABSL-2
NIH Section(s): III-D-4 and III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating research narrative details, IBC protocol checkboxes, and procedure descriptions for clarity, selecting appropriate PPE and laboratory cleaning checkboxes, updating BSC certification dates, and removing unnecessary procedures.

5. [redacted] **- # 1501: Probing and manipulating protein interactions**
Biosafety level: BSL-1, BSL-2
NIH Section(s): III-D-1, III-D-2, III-E-1, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating IBC protocol procedure details and checkboxes.

6. [redacted] **- # 1542: Mechanisms of mRNA surveillance**
Biosafety level: BSL-1, BSL-2
NIH Section(s): III-D-1, III-D-2, III-D-3, III-E-1, III-F

Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address updating IBC protocol checkboxes, procedures, research narrative details, and selecting appropriate PPE checkboxes.

7. [redacted] **- # 1660: Unraveling the epigenetic and transcriptional programs in immune cell dysregulation**
Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-3, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation to address minor administrative items including updating research narrative details for clarity, multiple IBC protocol section details, BSC certification details, and providing signs and symptoms for potentially infectious agents.

8. [redacted] **- # 1666: Human Immune System Mice as a pre-clinical model for human immunotherapies and studies of human immune responses**
Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address updating IBC protocol procedures, research narrative, and checkboxes for clarity.

9. [redacted] **- # 1670: Generation of genetically modified mice using molecular tools**
Biosafety level: BSL-1, BSL-2, ABSL-1
NIH Section(s): III-D-1, III-D-2, III-D-4, III-E-1, III-E-3, III-F
Approved = 13
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address updating research narrative details, adding details in multiple IBC protocol sections, and providing transportation/shipping documents as needed

X. Significant Amendment Reviews for Laboratory Protocols: None

XI. Exempt Protocols – New/Renewal:
1. [redacted] - # 1244: *Mechanotransduction in laboratory grown heart tissues*
2. [redacted] - # 1540: *Analysis of Reprometabolic Syndrome*
3. [redacted] - # 1544: *Understanding placental function in normal and pathological pregnancies.*

XII. Exempt Protocol Amendments:
1. [redacted] - # 1164 (x2): *Translational investigation of pediatric high-grade glioma*

2. [redacted] - # 1646: *Defining the Immune Mechanisms of Pediatric Cholestatic Liver Disease and Mouse Models of Obstructive Cholestasis*
3. [redacted] - # 1667: *Cell culture for 3D engineered tissues*

XIII. Additional Business: None

XIV. Next Meeting Scheduled: 16 November 2026, 9:00am (Mountain Time)

XV. Adjournment: 10:53am (Mountain Time).